GSK PLC announced plans to invest $30 billion in the United States over the next five years to boost its research, development, and manufacturing capabilities.
The investment includes a new $1.2 billion for advanced manufacturing facilities and technology, which will create hundreds of jobs, the company said on Wednesday.
A significant part of this new funding will go towards building a new biologics factory in Upper Merion, Pennsylvania, with construction set to begin in 2026.
According to the company, the facility will produce new medicines for respiratory diseases and cancer.
"Today, we are committing to invest at least $30 billion in the United States over the next 5 years, further bolstering the already strong R&D and supply chain we have in the country," CEO Emma Walmsley said in a statement.
The investment builds on approximately $2 billion in U.S. manufacturing commitments over the past year.
The broader $30 billion plan will also fund increased clinical trial activity, with the U.S. expected to become GSK's top location for studies, the company said.
The move comes as GSK reports strong sales growth, particularly in its specialty medicines division which includes respiratory and oncology drugs.
More from this issuer
Related coverage
GSK raised its full-year 2025 forecast on Wednesday, citing strong sales of its specialty medicines and vaccines and recent drug approvals, including for its cancer treatment Blenrep.
GSK said Thursday its cancer drug Blenrep won U.S. approval to treat adults with multiple myeloma that has returned or stopped responding to treatment, overcoming an earlier negative recommendation from a regulatory advisory panel.
GSK announced positive late-stage trial results for a new, low-carbon version of its widely used Ventolin asthma inhaler.
GSK and partner Alector said Tuesday their experimental drug for a rare form of dementia failed to meet its main goal in a late-stage trial.